de Ligt, K. M. http://orcid.org/0000-0001-9218-617X
Aaronson, N. K. http://orcid.org/0000-0003-2574-4850
Liegl, G. http://orcid.org/0000-0001-9073-817X
Nolte, S. http://orcid.org/0000-0001-6185-9423
,
Funding for this research was provided by:
European Organisation for Research and Treatment of Cancer (grant number 001 2015)
Charité - Universitätsmedizin Berlin
Article History
Accepted: 13 March 2023
First Online: 9 April 2023
Declarations
:
: SN: received grant EORTC Quality of Life Group grant #001 2015 (payments were made to Charité – Universitätsmedizin Berlin, Germany); was employed as a consultant/director by ICON plc from September 2018 to June 2021 and by Union Chimique Belge Biosciences GmbH from July 2021 until December 2021. The other authors declare that they have no competing interests.
: No ethics approval was sought as the study is based on panel data. According to the NHS Health Research Authority and the European Pharmaceutical Market Research Association (EphMRA), panel research does not require ethical approval if ethical guidelines are followed. The survey was distributed via the GfK SE (member of EphMRA) and obtained informed consent by each participant before the study. All data were collected anonymously and identification of the respondents through the authors is impossible.